Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy
Year: 2024
Type: article
Abstract: Cisplatin-based chemotherapy is used across many common tumor types, but resistance reduces the likelihood of long-term survival. We previously found the puromycin-sensitive aminopeptidase, NPEPPS, as a druggable driver of cisplatin resistance in vitro and in vivo and in patient-derived organoids. Here, we present a general mechanism where NPEPPS interacts with the volume-regulated anion channels (VRACs) to control cisplatin import into cells and thus regulate cisplatin response across a range of cancer types. We also find the NPEPPS/VRAC gene expression ratio is a predictive measure of cisplatin response in multiple cancer cohorts, showing the broad applicability of this mechanism. Our work describes a specific mechanism of cisplatin resistance, which, given the characteristics of NPEPPS as a drug target, has the potential to improve cancer patient outcomes. In addition, we describe an intracellular mechanism regulating VRAC activity, which is critical for volume regulation in normal cells - a finding with functional implications beyond cancer.
Source: Science Advances
Authors: Lily Elizabeth R. Feldman, Saswat Mohapatra, Robert T. Jones, Mathijs Scholtes, Charlene B. Tilton, Michael V. Orman, Molishree Joshi, Cailin S. Deiter, Travis P. Broneske, Fangyuan Qu, Corazon Gutierrez, Huihui Ye, Eric T. Clambey, Sarah Parker, Tokameh Mahmoudi, Tahlita Zuiverloon, James C. Costello, Dan Theodorescu
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,500
OpenAlex ID: W4405362578
